New pill could regrow hair in severe alopecia – trial begins
NCT ID NCT07617597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied patients are with their hair. It is a Phase 3, placebo-controlled study with an open-label extension, meaning all participants can receive the drug later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.